Routine obstetric medications and maternal heart rate variability
- Conditions
- hypertensive disorders of pregnancy (HDP), threatened preterm birth (TPB), preterm premature rupture of membranes (PPROM), vaginal blood loss
- Registration Number
- NL-OMON23599
- Lead Sponsor
- Philips Electronics Nederland B.V.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 61
Inclusion Criteria
Aged 18 years and above
-Gestational age 23 5/7 to 33 6/7 weeks upon admission
-Yet to receive second dose of antenatal corticosteroids
-Proficient in Dutch or English
Exclusion Criteria
-History of cardiovascular disease, specifically severe arrhythmia and congenital heart disease
-Cushing’s disease
-Known allergies for hard plastic (like in sport watches) or elastic band material.
-Presence of wounds, injuries or infectious diseases on the skin where the wrist-wearable device will be placed.
-Tattoo on top of wrist (where sensor should be placed)
-No space to place the device (as judged by the health care practitioner placing the device)
-Dexamethasone is given as antenatal corticosteroid instead of Betamethasone
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Investigate the effect of routine obstetric medications on maternal PPG features in complicated pregnancies, with specific focus on heart rate variability.
- Secondary Outcome Measures
Name Time Method Investigate PPG features of women who deliver preterm. <br>Investigate the PPG features throughout different stages of delivery (compared to CTG data) <br>Investigate differences in PPG features between normotensive and hypertensive subjects.<br>Investigate PPG features at 6 weeks postpartum.